mgus {survival}R Documentation

Monoclonal gammapothy data

Description

Natural history of 241 subjects with monoclonal gammapothy of undetermined significance (MGUS).

Usage

mgus
mgus1
mgus2

Format

mgus: A data frame with 241 observations on the following 12 variables.

id:

subject id

age:

age in years

sex:

male

or

female

dxyr:

year of diagnosis

pcdx:

for subjects who progress to a plasma cell malignancy

the subtype of malignancy: multiple myeloma (MM) is the

most common, followed by amyloidosis (AM), macroglobulinemia (MA),

and other lymphprolifative (LP)

pctime:

days from MGUS until diagnosis of a plasma cell malignancy

futime:

days from diagnosis to last follow-up

death:

1= follow-up is until death

alb:

albumin level at MGUS diagnosis

creat:

creatinine at MGUS diagnosis

hgb:

hemoglobin at MGUS diagnosis

mspike:

size of the monoclonal protien spike at diagnosis

mgus1: The same data set in start,stop format. Contains the id, age, sex, and laboratory variable described above along with

start, stop:

sequential intervals of time for each

subject

status:

=1 if the interval ends in an event

event:

the event type

mgus2: The mgus data, but formatted in the competing risks style. Each subject has three observations, one for time to death, one for time to MM, and one for time to a PC malignancy other than MM. Contains the id, age, sex, and laboratory variable described above along with

time:

time to event or censoring

status:

1 if the event occured, 0 otherwise

event:

death, myeloma, or other

Details

Plasma cells are responsible for manufacturing immunoglobulins, an important part of the immune defense. At any given time there are estimated to be about 10^6 different immunoglobulins in the circulation at any one time. When a patient has a plasma cell malignancy the distribuion will become dominated by a single isotype, the product of the malignant clone, visible as a spike on a serum protein electrophoresis. Monoclonal gammapothy of undertermined significance (MGUS) is the presence of such a spike, but in a patient with no evidence of overt malignancy. This data set of 241 sequential subjects at Mayo Clinic was the groundbreaking study defining the natural history of such subjects.

Source

Mayo Clinic data courtesy of Dr. Robert Kyle.

References

R Kyle, Benign monoclonal gammopathy – after 20 to 35 years of follow-up, Mayo Clinic Proc 1993; 68:26-36.


[Package survival version 2.36-9 Index]